NLRP3 and metabolic dysfunction-associated steatotic liver disease: JZLGD treatment decreased NLRP3, ASC, caspase-1, IL-1β, and IL-18 levels, suggesting that the mechanisms underlying the effects of JZLGD on HFD-induced NAFLD rats may be related to the NLRP3/caspase-1/GSDMD-mediated pyroptosis pathway.